Spectral Ai, Inc. Class A ( (MDAI) ) has released its Q2 earnings. Here is a breakdown of the information Spectral Ai, Inc. Class A presented to its investors.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Spectral AI, Inc. is a Dallas-based artificial intelligence company specializing in medical diagnostics, particularly in wound care, with its innovative DeepView System designed to enhance treatment decisions and patient outcomes. In its latest earnings report for the second quarter of 2025, Spectral AI reported a research and development revenue of $5.1 million, contributing to a total revenue of $11.8 million for the first half of the year. The company also highlighted a strong cash position of $10.5 million and the completion of its De Novo application submission to the FDA, marking a significant milestone for its DeepView System.
The financial results for Q2 2025 showed a decline in research and development revenue by 32% compared to the same period in 2024, primarily due to the completion of certain reimbursed study costs. Despite this, the company managed to reduce its general and administrative expenses to $4.4 million, reflecting its focus on operational efficiencies. However, the net loss for the quarter widened to $7.9 million, largely due to changes in the fair value of the company’s warrant liability.
Spectral AI’s financial condition remains robust with an improved cash position, bolstered by a debt financing agreement and equity financing. The company reiterated its revenue guidance of approximately $21.5 million for the full year 2025, excluding potential contributions from the commercialization of its DeepView System.
Looking ahead, Spectral AI remains committed to advancing its DeepView System and expanding its presence in the healthcare market. The management’s focus on innovation and operational efficiency positions the company to potentially capitalize on future growth opportunities in the medical diagnostics sector.